P04.16 Newborn affected by maternal use of amphetamines

Name of the Condition

• Newborn affected by maternal use of amphetamines (ICD-10-CM Code: P04.16)

Summary

This condition describes health effects in a newborn resulting from maternal use of amphetamines during pregnancy. The newborn may exhibit signs or symptoms due to transplacental exposure to these stimulant drugs, which can impact fetal development and postnatal health.

Causes

Maternal use of amphetamines during pregnancy can lead to fetal exposure via the placenta. These drugs, which stimulate the central nervous system, may cross the placenta and affect the developing fetus. The timing of exposure, maternal dosage, and frequency of use influence the newborn's condition.

Risk Factors

• Maternal use of amphetamines during pregnancy, particularly in the third trimester.
• High-dose or prolonged maternal exposure.
• Lack of prenatal monitoring for substance use.
• Co-use of other substances (e.g., alcohol, opioids) during pregnancy.

Symptoms

Symptoms in the newborn may include irritability, tremors, poor feeding, or withdrawal-like behaviors. Other manifestations can include respiratory distress, low birth weight, or abnormal vital signs. Some infants may exhibit hyperactivity or sleep disturbances.

Diagnosis

Diagnosis involves a review of maternal substance use history, newborn clinical assessment, and laboratory tests if needed. Documentation of maternal amphetamine use is critical for correlation with neonatal findings.

Treatment Options

Treatment focuses on managing symptoms and providing supportive care. This may include monitoring vital signs, addressing feeding difficulties, and using medications to alleviate withdrawal symptoms if present. Neonatal care should be tailored to the infant's specific needs.

Prognosis and Follow-Up

Prognosis depends on the extent of exposure and associated complications. Most newborns recover with appropriate care, but long-term effects on neurodevelopment may require ongoing monitoring. Follow-up assessments are recommended to evaluate growth, behavior, and developmental milestones.

Complications

Potential complications include growth restriction, congenital anomalies, or persistent neurodevelopmental issues. Severe cases may involve respiratory distress or seizures, requiring intensive care.

Lifestyle & Prevention

Prevention involves avoiding amphetamine use during pregnancy. Prenatal care should include screening for substance use, with support provided to mothers seeking to discontinue use. Education on the risks of stimulant exposure during pregnancy is essential.

When to Seek Professional Help

Seek medical attention if the newborn exhibits severe symptoms (e.g., difficulty breathing, seizures) or fails to feed adequately. Maternal care providers should be consulted for substance use support during pregnancy.

Tips for Medical Coders

Document maternal amphetamine use, including timing and duration of exposure, to support accurate coding. Ensure the newborn's clinical findings are clearly linked to maternal substance use. Use this code when the condition is directly attributable to maternal amphetamine exposure, with no other specific code applicable.